J Jassem

472 total citations
23 papers, 318 citations indexed

About

J Jassem is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J Jassem has authored 23 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in J Jassem's work include Cancer Immunotherapy and Biomarkers (3 papers), Peptidase Inhibition and Analysis (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). J Jassem is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Peptidase Inhibition and Analysis (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). J Jassem collaborates with scholars based in Poland, Sweden and United States. J Jassem's co-authors include C.-M. Rudenstam, Ole Erik Iversen, Mats Hammar, O Peralta, Janusz Jaśkiewicz, Hans E. Fjøsne, R. Arriagada, E. Kumpulainen, Lars Holmberg and Marit Holmqvist and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

J Jassem

22 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Jassem Poland 8 155 140 118 63 49 23 318
Angela Bowman United Kingdom 12 118 0.8× 108 0.8× 37 0.3× 67 1.1× 40 0.8× 16 407
Kyle Gilmour United Kingdom 5 96 0.6× 186 1.3× 210 1.8× 16 0.3× 41 0.8× 7 375
Silvia Pecchio Italy 8 143 0.9× 67 0.5× 53 0.4× 43 0.7× 105 2.1× 13 306
Ole‐Erik Iversen Norway 11 68 0.4× 53 0.4× 61 0.5× 61 1.0× 68 1.4× 26 346
Mei‐Tzu C. Tang United States 10 231 1.5× 69 0.5× 60 0.5× 33 0.5× 109 2.2× 26 379
Renzo Grattarola Italy 9 122 0.8× 161 1.1× 87 0.7× 48 0.8× 48 1.0× 32 318
Sabrina Witherby United States 7 83 0.5× 49 0.3× 77 0.7× 32 0.5× 27 0.6× 11 188
P Cohen United States 9 97 0.6× 131 0.9× 23 0.2× 42 0.7× 57 1.2× 20 347
J. Van Loon Netherlands 8 67 0.4× 94 0.7× 34 0.3× 38 0.6× 73 1.5× 20 258
Antonino Bonaventura Australia 7 186 1.2× 183 1.3× 20 0.2× 69 1.1× 160 3.3× 15 329

Countries citing papers authored by J Jassem

Since Specialization
Citations

This map shows the geographic impact of J Jassem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Jassem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Jassem more than expected).

Fields of papers citing papers by J Jassem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Jassem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Jassem. The network helps show where J Jassem may publish in the future.

Co-authorship network of co-authors of J Jassem

This figure shows the co-authorship network connecting the top 25 collaborators of J Jassem. A scholar is included among the top collaborators of J Jassem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Jassem. J Jassem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gregorc, Vanesa, Rabab Gaafar, Adolfo Favaretto, et al.. (2015). 3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). European Journal of Cancer. 51. S634–S634. 1 indexed citations
2.
3.
Zandwijk, Nico van, Paul Roepman, Sjaak A. Burgers, et al.. (2009). Expression of thymidylate synthase (TYMS) and Insulin growth factor 1 (IGF1) in completely-resected NSCLC patients: associations with histological subtype and prognosis. Pure Amsterdam UMC. 4(9). 1 indexed citations
4.
Jassem, J, Johan Vansteenkiste, M. Zieliński, et al.. (2008). GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology. 19. 61–61. 2 indexed citations
5.
Holmberg, Lars, Ole Erik Iversen, C.-M. Rudenstam, et al.. (2008). Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors. JNCI Journal of the National Cancer Institute. 100(7). 475–482. 215 indexed citations
6.
Jassem, J, Maciej Bobowicz, Jan Marek Słomiński, & Ewa Jassem. (2007). The incidence of chronic obstructive pulmonary disease in advanced non-small cell lung cancer patients. 6(3). 99–102. 5 indexed citations
7.
Chodorowski, Z, Jacek Sein Anand, J Jassem, et al.. (2007). [Late recurrence of malignant tumours 20 years after diagnosis and treatment].. PubMed. 64(4-5). 372–3. 2 indexed citations
8.
Jassem, Ewa, Krystyna Serkies, Rafał Dziadziuszko, et al.. (2006). Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer. Biomarkers. 11(3). 262–269. 5 indexed citations
9.
Siemińska, Alicja, et al.. (2006). Tobacco Smoking among the First-Year Medical Students. Advances in respiratory medicine. 74(4). 377–382. 7 indexed citations
10.
Boyer, Michael, J Jassem, James T. Symanowski, et al.. (2003). O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 41. S19–S19. 13 indexed citations
11.
Dziadziuszko, Rafał, L Chyczewski, Ewa Jassem, & J Jassem. (2001). Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report.. PubMed. 39 Suppl 2. 100–1. 12 indexed citations
12.
13.
Wełnicka-Jaśkiewicz, Marzena, et al.. (1999). The occurrence of cerebellar hemangioblastoma in numerous first degree relatives with von Hippel-Lindau disease.. PubMed. 37(3). 175–8. 4 indexed citations
14.
Wójcik, Janusz, et al.. (1998). [Platinum-based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature].. PubMed. 5(27). 145–6. 1 indexed citations
15.
Jassem, Ewa, R. Rosell, J Jassem, et al.. (1998). [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].. PubMed. 66(5-6). 290–6. 1 indexed citations
16.
Jassem, J, et al.. (1996). Sarcoma of the uterus. Archives of Gynecology and Obstetrics. 258(4). 171–180. 14 indexed citations
17.
Senkus, Elżbieta, J Jassem, H Karnicka-Młodkowska, et al.. (1994). [Analysis of prognostic factors for long term survival in patients with small cell lung cancer].. PubMed. 62(5-6). 233–8. 2 indexed citations
18.
Eckhardt, S., Krsto Kolarić, J Jassem, et al.. (1990). Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG).. PubMed. 7(1). 19–23. 7 indexed citations
19.
Jassem, J & Krystyna Serkies. (1980). Skin reactivity to dinitrochlorobenzene in cancer patients.. PubMed. 27(5). 589–93.
20.
Jassem, J, et al.. (1980). [Autoantibodies in patients with malignant tumors].. PubMed. 29(4). 253–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Bowman Breakdown of academic impact, for papers by Kyle Gilmour Breakdown of academic impact, for papers by Silvia Pecchio Breakdown of academic impact, for papers by Ole‐Erik Iversen Breakdown of academic impact, for papers by Mei‐Tzu C. Tang Breakdown of academic impact, for papers by Renzo Grattarola Breakdown of academic impact, for papers by Sabrina Witherby Breakdown of academic impact, for papers by P Cohen Breakdown of academic impact, for papers by J. Van Loon Breakdown of academic impact, for papers by Antonino Bonaventura
Rankless by CCL
2026